Introduction {#s1}
============

Various glucose parameters have been used to predict poor stroke outcomes but remain controversial ([@B1]). Several studies have shown that glycated hemoglobin (HbA1c), reflecting prestroke chronic hyperglycemia, was associated with poor functional outcomes after stroke ([@B2]--[@B4]). Nonetheless, a recent experimental study showed that glycemic variability could trigger more oxidative stress and both microvascular and macrovascular injury than chronic hyperglycemia ([@B5], [@B6]). Hence, prestroke glycemic variability could be more associated with stroke outcomes than prestroke chronic hyperglycemia.

A consensus on the gold standard method to measure glycemic variability in clinical practice and research is still lacking ([@B1]). The easiest way to measure glycemic variability is to estimate the standard deviation (SD) of the mean blood glucose and the coefficient of variation (CV). However, since this method requires data from at least 2 consecutive days after stroke onset to perform the estimation, SD and CV could not be appropriate indexes of prestroke glycemic variability to predict outcomes of acute ischemic stroke.

Glycated albumin (GA) reflects glycemic variability within 4 weeks of stroke onset ([@B7], [@B8]), so GA could be a useful marker for predicting prestroke glycemic variability. Additionally, GA is measured quickly and easily with one blood sample.

The relationship between prestroke glycemic variability and initial stroke severity and infarct size on diffusion-weighted imaging (DWI) has not been assessed previously. In this study, we investigated the effects of glycemic variability measured by GA on stroke severity and infarct volume on DWI compared with using HbA1c in individuals with diabetes mellitus (DM) presenting with acute ischemic stroke.

Methods {#s2}
=======

Subjects
--------

We prospectively registered all acute ischemic stroke patients between March 2016 and May 2019 in our institution. For the purpose of this study, we included only patients who had an established diagnosis of DM (HbA1c value ≥ 6.5%) ([@B9]) at the time of hospitalization or who had a history of or used hypoglycemic agents or insulin. In this study, we excluded the following patients: (1) patients with unavailable GA and brain magnetic resonance imaging (MRI) data. (2) Patients with transient ischemic attacks without ischemic lesions visible on MRI performed within 24 h of stroke onset.

Data Collection and Definition of Parameters
--------------------------------------------

The following data were directly obtained from the registry database: (1) Demographics including age and sex; (2) stroke risk factors, medical history, prior stroke, hypertension, DM, hyperlipidemia, atrial fibrillation, current smoking, and prior use of antithrombotic drugs; (3) stroke characteristics, acute stroke treatment, initial NIHSS score, ischemic stroke mechanism according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification, and reperfusion therapy; (4) laboratory data including hemoglobin, creatinine, initial random glucose, total cholesterol, low-density lipoprotein, high-sensitivity C-reactive protein (hs-CRP), HbA1c, serum albumin, and systolic blood pressure.

The primary outcome measure was the categorized initial stroke severity assessed by NIHSS score at the time of hospitalization (mild: NIHSS 0--5, moderate: NIHSS 6--14, and severe: NIHSS \> 14) ([@B10], [@B11]). The secondary outcome measure was the ischemic lesion volumes on DWI calculated by Medical Image Processing and Visualization software (MIPAV, version 7.3.0, National Institutes of Health, Bethesda, MD). Acute ischemic lesions were identified on a slice-by-slice basis and were correlated with low signals on apparent diffusion coefficients. DWI infarct volumes were calculated by multiplying slice thickness by total areas of lesions. Two experienced neurologists (S-H Lee and MU Jang) assessed all infarct volumes on DWI (interclass correlation coefficient = 0.87). The infarct volumes were divided into quartiles and denoted as Q-25, Q-50, Q-75, and Q-100. Q-25 indicated the lowest quartile of DWI infarct volume, and Q-100 indicated the highest quartile.

Measurement of GA Level
-----------------------

Venous blood was drawn from fasting patients within 12 h after admission. The serum specimens were collected and measured by an enzymatic method using albumin-specific proteinase and ketoamine oxidase (Lucica GA-L; ASAHI KASEI PHARMA, Japan) ([@B12]). Several studies suggested the cutoff point of GA to identify DM ([@B8]). A study with a large population (*n* = 2,192) in Taiwan described a cutoff point of GA ≥ 14.5% for DM. In addition, when the value of 6.5% of HbA1c was considered, the corresponding GA was 16.5%. Another study with a relatively large population (*n* = 1575) in Japan described the cutoff point of GA ≥ 15.5%. Hence, we established that a GA level ≥ 16.0% reflected the presence of glycemic variability prior to ischemic stroke based on the following equation of HbA1c and GA: HbA1c = 0.216 × GA +2.978 ([@B13]). According to GA levels, we divided the population into a lower GA group (GA \< 16.0%) and a higher GA group (GA ≥ 16.0%).

Statistical Analysis
--------------------

We assumed that higher GA levels, which indicate high glycemic variability prior to the stroke, could be associated with initial stroke severity and infarct volume.

Summary statistics are presented as the number of subjects (percentage) for categorical variables and as the mean ± SD or median (interquartile range, IQR) for continuous variables. Group comparisons were made using Pearson\'s chi-squared test for categorical variables and Student\'s *t*-test or the Mann-Whitney U-test for continuous variables, where appropriate.

With respect to the primary and secondary outcome measures, the lower GA group and the higher GA group were compared using Pearson\'s chi-squared test, and independent effects of GA on those outcome measures were analyzed using multinomial logistic regression and multiple linear regression models. Variables for adjustment in the multivariable analysis were selected if their *p*-values were \<0.2 in comparisons according to the GA level and if their associations with each outcome variable were clinically plausible. Crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated.

In a sensitivity analysis, we also analyzed whether HbA1c could affect primary and secondary outcomes. Crude and multivariable analyses were performed according to dichotomized HbA1c (\<6.5% vs. ≥ 6.5%). In addition, we included the ratio of GA to HbA1c (GA/HbA1c ratio) in multinomial logistic regression analysis because the GA/HbA1c ratio could reflect more accurate glycemic control ([@B14]). The impact of elevated HbA1c and GA/HbA1c ratio on outcomes was assessed by multinomial logistic regression analysis. Moreover, we categorized GA and HbA1c into tertiles and analyzed the effects on outcomes.

In a subgroup analysis, we analyzed whether GA could affect outcomes according to stroke mechanisms (large artery atherosclerosis \[LAA\], small vessel occlusion \[SVO\], and cardioembolism \[CE\]). Since the sample size was small for each stroke mechanism, we dichotomized NIHSS scores as mild (NIHSS 0--5) and moderate to severe (NIHSS 6--42) ([@B11]). All data analyses were performed with IBM SPSS version 21.0 software (IBM Corporation, Armonk, NY, USA).

Results {#s3}
=======

Among the 761 consecutive patients with acute ischemic stroke, 296 patients diagnosed with DM (175 males and 121 females, aged 70.4 ± 11.5 years) were included in the study throughout the study period. Of the 296 patients, 217 (73.3%) were in the higher GA group (GA ≥ 16.0%) and 203 (68.6%) were in the high HbA1c group (HbA1c ≥ 6.5%). The higher GA group was more likely to have a higher HbA1c level, initial random glucose, and larger infarct volume. The higher GA group tended to have more severe stroke symptoms than the lower GA group (*p* = 0.052). In non-diabetic patients (*n* = 465) in the present study, the initial NIHSS score was 3 (IQR 1--6) in the lower GA group and 4 (IQR 1--10) in the higher GA group (*p* = 0.01, data were not shown). We carefully suggest that the higher GA group seems to have more severe stroke symptoms in both DM and non-diabetic patients presenting with acute ischemic stroke. Generally, the stroke characteristics and demographics were not different between the lower GA and higher GA groups ([Table 1](#T1){ref-type="table"}). Compared with the results according to GA levels, stroke severity and infarct volumes were not significantly different according to HbA1c levels ([Supplemental Table 1](#SM1){ref-type="supplementary-material"}). Despite well-controlled DM patients having HbA1c levels \<6.5%, half had higher GA levels (48.4%). Pearson\'s correlation analysis showed that the raw GA was significantly positively correlated with both initial NIHSS scores (*r* = 0.20; *p* \< 0.001) and DWI infarct volumes (*r* = 0.35, *p* \< 0.001) ([Supplemental Figure 1](#SM1){ref-type="supplementary-material"}).

###### 

Baseline characteristics of the study population (*n* = 296) according to GA levels.

                                                         **Lower GA group (GA \<16.0%) *n* = 79**   **Higher GA group (GA ≥ 16.0%) *n* = 217**   ***p*-value**
  ------------------------------------------------------ ------------------------------------------ -------------------------------------------- ---------------------------------------
  Age, years (SD)                                        70.8 (11.8)                                70.2 (11.4)                                  0.67[^†^](#TN2){ref-type="table-fn"}
  Male (%)                                               44 (55.7)                                  131 (60.4)                                   0.51[^\*^](#TN1){ref-type="table-fn"}
  BMI, kg/m^2^ (SD)                                      24.2 (3.4)                                 24.5 (3.7)                                   0.82[^†^](#TN2){ref-type="table-fn"}
  Interval from onset to visit, hours \[median (IQR)\]   14.8 (5.3--50.0)                           12.9 (3.7--38.4)                             0.35[^‡^](#TN3){ref-type="table-fn"}
  History of stroke (%)                                  23 (29.1)                                  59 (27.2)                                    0.77[^\*^](#TN1){ref-type="table-fn"}
  Hypertension (%)                                       64 (81.0)                                  158 (72.8)                                   0.17[^\*^](#TN1){ref-type="table-fn"}
  Duration of DM, year (SD)                              7.3 (2.7)                                  5.2 (2.7)                                    0.18[^†^](#TN2){ref-type="table-fn"}
  Hyperlipidemia (%)                                     17 (21.5)                                  34 (15.7)                                    0.30[^\*^](#TN1){ref-type="table-fn"}
  Current smoking (%)                                    12 (15.2)                                  28 (12.9)                                    0.70[^\*^](#TN1){ref-type="table-fn"}
  Atrial fibrillation (%)                                15 (19.0)                                  39 (18.0)                                    0.87[^\*^](#TN1){ref-type="table-fn"}
  Coronary artery disease (%)                            6 (7.6)                                    20 (9.2)                                     0.82[^\*^](#TN1){ref-type="table-fn"}
  Prior antithrombotic agents (%)                        41 (51.9)                                  96 (44.2)                                    0.29[^\*^](#TN1){ref-type="table-fn"}
  Initial NIHSS score (IQR)                              4 (2--6)                                   5 (2--11)                                    0.052[^‡^](#TN3){ref-type="table-fn"}
  Stroke mechanism (%)                                                                                                                           0.14[^\*^](#TN1){ref-type="table-fn"}
   SVO                                                   27 (34.2)                                  51 (23.5)                                    
   LAA                                                   28 (35.4)                                  97 (44.7)                                    
   CE                                                    16 (20.3)                                  35 (16.1)                                    
   Others                                                8 (10.1)                                   34 (15.7)                                    
  Reperfusion therapy (%)                                9 (11.4)                                   28 (12.9)                                    0.84[^\*^](#TN1){ref-type="table-fn"}
  Ischemic lesions (%)                                                                                                                           0.92[^\*^](#TN1){ref-type="table-fn"}
   Supratentorial                                        53 (67.1)                                  147 (67.7)                                   
   Infratentorial                                        26 (32.9)                                  70 (32.3)                                    
  Laboratory data                                                                                                                                
  Total cholesterol, mg/dL (SD)                          153.8 (46.9)                               155.2 (43.0)                                 0.51[^†^](#TN2){ref-type="table-fn"}
  Hemoglobin, g/dL (SD)                                  13.1 (1.9)                                 13.5 (2.2)                                   0.48[^†^](#TN2){ref-type="table-fn"}
  Creatinine, mg/dL (SD)                                 1.1 (0.9)                                  1.1 (0.6)                                    0.33[^†^](#TN2){ref-type="table-fn"}
  Platelets, ×1,000/μL (SD)                              228.3 (70.2)                               228.1 (80.3)                                 0.51[^†^](#TN2){ref-type="table-fn"}
  hs-CRP, mg/L (SD)                                      10.8 (27.4)                                12.3 (28.8)                                  0.66[^†^](#TN2){ref-type="table-fn"}
  LDL, mg/dL (SD)                                        51.3 (31.4)                                45.9 (31.6)                                  0.38[^†^](#TN2){ref-type="table-fn"}
  HbA1c, % (SD)                                          6.3 (1.0)                                  7.6 (1.5)                                    0.002[^†^](#TN2){ref-type="table-fn"}
  Initial random glucose, mg/dL (SD)                     150.6 (55.9)                               182.7 (74.1)                                 0.02[^†^](#TN2){ref-type="table-fn"}
  Serum albumin, mg/dL (SD)                              3.88 (0.30)                                3.85 (0.42)                                  0.08[^†^](#TN2){ref-type="table-fn"}
  SBP, mmHg (SD)                                         150.0 (26.4)                               148.6 (25.2)                                 0.43[^†^](#TN2){ref-type="table-fn"}
  Infarct volume, cm^3^, median (IQR)                    0.46 (0.21--2.21)                          1.77 (0.41--33.15)                           \<0.001

*GA, glycated albumin; SD, standard deviation; BMI, body mass index; IQR, interquartile range; DM, diabetes mellitus; NIHSS, National Institute Health of Stroke Scale; SVO, small vessel occlusion; LAA, large artery atherosclerosis; CE, cardioembolism; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; HbA1c, glycated hemoglobin; SBP, systolic blood pressure*.

*Calculated using the chi-square test*.

*Calculated using Student\'s t-test*.

*Calculated using Mann-Whitney U test*.

The proportion of individuals with moderate and severe stroke (NIHSS 6--14 and NIHSS \> 14) was higher in the higher GA group than in the lower GA group (moderate: 27.8% vs. 29.0% and severe: 3.8% vs. 15.7%, *p* = 0.01, [Figure 1](#F1){ref-type="fig"}). The proportion of individuals in the highest quartile of DWI infarct volume (Q-100) was higher in the GA group than in the GA group (11.4% vs. 36.4%, *p* \< 0.001, [Figure 2](#F2){ref-type="fig"}). Additionally, in non-DM patients, the higher GA group had either more severe stroke (NIHSS 6--14 and NIHSS \> 14) or DWI infarct volume (Q-100) ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}).

![Distributions of initial stroke severity by categorized NIHSS scores according to GA levels in both DM and non-DM patients. NIHSS, National Institutes of Health Stroke Scale; GA, glycated albumin; DM, diabetic mellitus.](fendo-11-00230-g0001){#F1}

![Distributions of quartiles of infarct volumes according to GA levels in both DM and non-DM patients. GA, glycated albumin; DM, diabetic mellitus.](fendo-11-00230-g0002){#F2}

The multinomial logistic regression analysis showed that higher GA levels were significantly associated with severe stroke (adjusted OR, \[95% CI\], 7.99 \[1.75--36.45\], [Table 2](#T2){ref-type="table"} and [Supplemental Table 2](#SM1){ref-type="supplementary-material"}). The linear regression analysis showed that raw GA was also significantly positively correlated with initial NIHSS scores (*r*^2^ = 0.16, *p* \< 0.001, [Supplemental Table 3](#SM1){ref-type="supplementary-material"}). Additionally, higher GA was significantly associated with the highest quartile (Q-100) of DWI infarct volumes (adjusted OR \[95% CI\]; 3.76 \[1.05--13.45\], [Table 3](#T3){ref-type="table"} and [Supplemental Table 4](#SM1){ref-type="supplementary-material"}). The linear regression analysis showed that raw GA was also significantly positively correlated with initial NIHSS scores (*r*^2^ = 0.25, *p* = 0.002, [Supplemental Table 5](#SM1){ref-type="supplementary-material"}).

###### 

Multinomial logistic regression analysis: impact of higher GA (≥16.0%) on initial stroke severity (reference = NIHSS 0--5).

                   **GA** **≥** **16.0% (*****n*** **=** **217)**   **HbA1c** **≥** **6.5% (*****n*** **=** **203)**   **GA/HbA1c ratio**                       
  ---------------- ------------------------------------------------ -------------------------------------------------- -------------------- ------------ ------ -------------
  **NIHSS 0--5**   **Reference**                                                                                                                                
  NIHSS 6--14      1.25                                             0.62--2.51                                         0.88                 0.44--1.76   2.27   1.22--4.20
  NIHSS \>14       7.99                                             1.75--36.45                                        2.32                 0.76--7.14   5.21   2.11--12.86

*GA, glycated albumin; NIHSS, National Institutes Health of Stroke Scale; HbA1c, glycated hemoglobin; OR, odds ratio; CI, confidence interval*.

*Adjusted for age, sex, hypertension, stroke mechanism, stroke severity, medications for hypertension, medications for DM, prior antithrombotic agents use, statin use, initial random glucose, serum albumin, and glycated hemoglobin*.

*Adjusted for age, sex, prior stroke, stroke mechanism, stroke severity, interval from onset to visit, current smoking, prior antithrombotic agents use, atrial fibrillation, reperfusion therapy, medications for DM, previous antithrombotic agents, statin use, creatinine, low-density lipoprotein, glycated hemoglobin and initial random glucose*.

###### 

Multinomial logistic regression analysis: impact of higher GA (≥16.0%) on each quartile of infarct volume (reference = Q-25).

             **GA ≥ 16.0% (*****n*** **= 217)**   **HbA1c ≥ 6.5% (*****n*** **= 203)**   **GA/HbA1c ratio**                        
  ---------- ------------------------------------ -------------------------------------- -------------------- ------------- ------ ------------
  **Q-25**   **Reference**                                                                                                         
  Q-50       1.58                                 0.65--3.88                             2.59                 1.04--6.48    0.91   0.41--2.01
  Q-75       1.48                                 0.56--3.97                             2.77                 1.01--7.62    0.66   0.27--1.64
  Q-100      3.76                                 1.05--13.45                            3.39                 1.08--10.69   2.95   1.29--6.75

*GA, glycated albumin; HbA1c, glycated hemoglobin; OR, odds ratio; CI, confidence interval*.

*Adjusted for age, sex, hypertension, stroke mechanism, stroke severity, medications for hypertension, medications for DM, prior antithrombotic agents use, statin use, initial random glucose, serum albumin, and glycated hemoglobin*.

*Adjusted for age, sex, prior stroke, stroke mechanism, stroke severity, interval from onset to visit, current smoking, prior antithrombotic agents use, atrial fibrillation, reperfusion therapy, medications for DM, previous antithrombotic agents, statin use, creatinine, low-density lipoprotein, glycated hemoglobin and initial random glucose*.

A sensitivity analysis was performed to evaluate the impact of HbA1c on stroke severity and DWI infarct volume. HbA1c ≥ 6.5% was not associated with initial stroke severity but was associated with increasing DWI infarct volume ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} and [Supplemental Tables 6, 7](#SM1){ref-type="supplementary-material"}). The GA/HbA1c ratio was also associated with both severe stroke severity (initial NIHSS score \> 14) and the highest quartile of DWI infarct volume (Q-100) ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). We categorized GA and HbA1c into tertiles and analyzed the effect on stroke severity and DWI infarct volume. The highest tertile of GA was associated with both severe stroke symptoms and the highest quartile (Q-100) of DWI infarct volume. The highest tertile of HbA1c was not associated with initial stroke severity but was associated with the highest quartile (Q-100) of DWI infarct volume ([Supplemental Tables 10](#SM1){ref-type="supplementary-material"}, **11**).

As shown in [Table 1](#T1){ref-type="table"}, the LAA group was 125, the SVO group was 78 and the CE group was 51 in this study. When the patients were stratified by stroke mechanism, the effects of GA on moderate-to-severe stroke symptoms (NIHSS 6--42) and the highest quartile of DWI infarct volume (Q-100) were statistically significant for only LAA (*p* = 0.04 and 0.01, respectively), whereas they were not significant for SVO or CE in the multivariable analysis ([Supplemental Tables 8](#SM1){ref-type="supplementary-material"}, **9**).

Discussion {#s4}
==========

The main findings of this study were as follows: (1) the higher GA group had severe stroke symptoms and large infarct volume; (2) a higher GA and higher GA/HbA1c ratio could be associated with severe initial stroke severity and higher infarct volume in acute ischemic stroke patients with DM; (3) a high HbA1c, which represents chronic hyperglycemia prior to stroke, was not associated with initial stroke severity but was associated with increasing infarct volume.

Several studies have shown that exposure of cell cultures to rapid glycemic fluctuations produced more oxidative stress and severe cellular damage than exposure to continuous high glucose, thereby aggravating micro- and macroangiopathy ([@B15]--[@B18]). Several studies on humans also demonstrated that oscillating glucose was more damaging to endothelial function than sustained hyperglycemia in the context of type 2 diabetes ([@B5], [@B6]). Free radicals produced by inadequate intracellular antioxidant processes and oxidative stress seem to account for these phenomena ([@B19]). The present study could support the aforementioned ideas. Several studies on stroke outcome have focused on prestroke chronic hyperglycemia ([@B2], [@B4], [@B20]--[@B25]), but the impact of prestroke glycemic variability on acute stroke outcomes has not been investigated. We suggest that our results could increase the interest in the clinical implications of the impact of prestroke glycemic variability on acute stroke outcomes.

In the present study, high GA, reflecting recent glycemic variability ([@B7], [@B26]), could increase the risk of initial severe stroke symptoms and infarct volume. Compared to HbA1c, GA more accurately reflects short-term glucose fluctuation, postprandial hyperglycemia, and fasting hyperglycemia and thus is useful for monitoring glycemic variability ([@B7], [@B8], [@B26]). Interestingly, we found that among the patients with well-controlled DM (HbA1c \<6.5%), approximately half (48.4%) had higher GA levels in the present study. This result indicated that glycemic fluctuations may occur frequently in DM patients who are regarded as having well-controlled glycemia or those with poor drug compliance but without clinical diabetic symptoms. Hence, GA could be clinically more useful for monitoring glycemic control than time-averaged mean glucose concentration represented by HbA1c. Additionally, GA may be recommended in individuals with pathological conditions such as hematologic disease and chronic kidney disease, which account for a large proportion of stroke patients ([@B27]--[@B29]). Therefore, although GA testing has not been widely used in the laboratory setting, our study carefully suggested that GA could be a useful potential predictor for the acute outcome of diabetic patients with acute ischemic stroke.

The previous results of the associations between HbA1c and initial stroke severity and infarct volumes remain controversial ([@B2], [@B23]). A previous study (*n* = 96) showed that HbA1c could be associated with initial stroke severity and infarct volume in brainstem infarction among DM and non-DM patients. Another previous study (*n* = 375) showed that HbA1c was associated with infarct growth in only non-DM patients with arterial occlusion. Notably, our results showed that HbA1c was not associated with initial stroke severity but was associated with increasing infarct volume in DM patients. However, when we categorized the HbA1c into tertiles, only the highest tertile of HbA1c was associated with the highest DWI infarct volume. We carefully suggest that the small sample size and the heterogeneity of the populations in each study could lead to the disparities in the results. Additionally, the influence of chronic hyperglycemia seems to be different between DM and non-DM patients ([@B21]). Further study on this issue with a large population is needed to demonstrate this controversy.

Interestingly, the impact of GA on acute stroke outcomes was different according to the stroke mechanism in this study. Significant associations of GA and moderate-to-severe stroke (NIHSS \> 5) and larger infarct volumes were found in only LAA, whereas not in SVO or CE. GA may be an excellent marker of diabetic complications, especially macrovascular disease ([@B30]). HbA1c is a good marker of microvascular complications, and it seems to be less useful for macrovascular complications ([@B31]). Acute glucose fluctuation has been postulated to contribute to the pathogenesis of atherosclerosis, including cardiovascular complications ([@B5], [@B6]). With regard to this evidence, the particular association between GA and acute stroke outcomes in LAA could be explained. Nonetheless, we should be cautious regarding generalizing the results because of the relatively small sample size. We carefully point out the possibility that GA has different effects on the outcomes according to stroke mechanisms.

Although we evaluated the impact of prestroke glycemic variability measured by GA on acute stroke outcomes for the first time, several limitations of our study should be noted. First, this was a single-center study with a relatively small number of subjects, despite the use of a prospective database. Second, although we controlled for several confounders in our statistical models, we could not completely exclude the effects of unmeasured confounding variables. Third, we measured GA only at baseline and not serially. The detection of serial changes in GA may be more valuable for predicting outcomes of acute ischemic stroke. Fourth, we did not consider conditions of increasing protein metabolism that affect GA levels, such as thyroid dysfunction, liver cirrhosis, nephrotic syndrome, and other specific medical conditions ([@B32]). However, age, body mass index, creatinine, serum albumin, and high-sensitivity C-reactive protein levels were not different according to GA levels. Despite data being unavailable for detailed inflammation laboratory tests, thyroid and liver function tests in our database, this lack of differences in laboratory tests could support our results. Recently, alcohol consumption was shown to reduce the level of GA by deteriorating glucose tolerance ([@B33]). Unfortunately, alcohol consumption was not available in our registry database. Further study on this issue will include the alcohol consumption in DM patients. Fifth, although GA could be postulated as a marker of recent glycemic variability, validation of GA was not performed in this study. Hence, we should be cautious regarding generalizing our results.

Conclusions {#s5}
===========

The present study suggests that prestroke glycemic variability is associated with initial severe stroke symptoms and large infarct volume in DM patients presenting with acute ischemic stroke. Although further studies are warranted to investigate these issues, monitoring prestroke glycemic variability via GA testing during hospitalization could raise the possibility and interest for predicting outcomes in diabetic patients with acute ischemic stroke. Additionally, measured with HbA1c, the clinical significance of GA measurement could be increased.
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